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ABSTRACT
Introduction: Liver cirrhosis can have a major impact
on drug pharmacokinetics and pharmacodynamics.
Patients with cirrhosis often suffer from potentially
preventable adverse drug reactions. Guidelines on safe
prescribing for these patients are lacking. The aim of
this study is to develop a systematic method for
evaluating the safety and optimal dosage of drugs in
patients with liver cirrhosis.
Methods and analysis: For each drug, a six-step
evaluation process will be followed. (1) Available
evidence on the pharmacokinetics and safety of a drug
in patients with liver cirrhosis will be collected from the
Summary of Product Characteristics (SmPC) and a
systematic literature review will be performed. (2) Data
regarding two outcomes, namely pharmacokinetics and
safety, will be extracted and presented in a
standardised assessment report. (3) A safety
classification and dosage suggestion will be proposed
for each drug. (4) An expert panel will discuss the
validity and clinical relevance of this suggested advice.
(5) Advices will be implemented in all relevant Clinical
Decision Support Systems in the Netherlands and
published on a website for patients and healthcare
professionals. (6) The continuity of the advices will be
guaranteed by a yearly check of new literature and
comments on the advices. This protocol will be applied
in the evaluation of a selection of drugs: (A) drugs
used to treat (complications of ) liver cirrhosis, and (B)
drugs frequently prescribed to the general population.
Ethics and dissemination: Since this study does
not directly involve human participants, it does not
require ethical clearance. Besides implementation on a
website and in clinical decision support systems, we
aim to publish the generated advices of one or two
drug classes in a peer-reviewed journal and at
conference meetings.
INTRODUCTION
Liver cirrhosis is a slowly progressive disease
characterised by ﬁbrosis and conversion of
normal liver architecture into structurally
abnormal nodules. Liver cirrhosis results from
ongoing inﬂammation of the liver.1 Clinical
symptoms ensue because the hepatic architec-
ture is affected, which results in increased vas-
cular resistance in the liver and portal
hypertension.1 Liver cirrhosis has an import-
ant impact on healthcare worldwide. In 2010,
more than one million people died of liver
cirrhosis, which was almost 2% of global
deaths.2 3 The Child-Pugh score classiﬁes the
severity of liver cirrhosis and predicts mortal-
ity.4 It is also recommended by the medicine
registration authorities in Europe and the
USA for use in pharmacokinetic studies.5 6
The liver is the main organ for metabolism
and detoxiﬁcation of endogenous and
exogenous substances. Several pathophysio-
logical changes that occur in liver cirrhosis
inﬂuence this detoxiﬁcation of exogenous
substances, that is, drug pharmacokinetics.7–9
Portal vein shunting increases oral absorp-
tion of drugs with a high hepatic extraction
ratio through a bypass of the liver. Decreased
plasma protein synthesis causes lower plasma
Strengths and limitations of this study
▪ This is the first protocol describing a six-step
method to develop advices about the safety of
drugs in patients with liver cirrhosis. The first
four steps involve gathering evidence and an
assessment by an expert panel. Steps five and
six consist of implementing prescribing advice in
all relevant clinical decision support systems in
the Netherlands and regularly updating the
advices.
▪ We have designed a safety classification to
support healthcare providers and patients to effi-
ciently judge drug safety in liver cirrhosis.
▪ A potential limitation of this protocol is the
number of published studies available concerning
the use of drugs in patients with liver cirrhosis.
However, the combination with expert opinion
will make it possible to give specific advices.
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protein concentrations and possibly a higher fraction of
unbound drug. A reduction or impairment of drug-
metabolising enzymes in the liver may cause reduced
metabolism. These changes often result in an elevated
drug exposure, possibly causing side effects and tox-
icity.7–9 It is also important to consider changes in
pharmacodynamics. Hence, the efﬁcacy of drugs could
be different in patients with liver cirrhosis. Moreover,
patients with cirrhosis are more vulnerable to certain
adverse drug reactions (ADRs), such as effects on coagu-
lation or nephrotoxicity.7 8
In patients with liver cirrhosis, 20% of the drugs are
dosed incorrectly and almost 30% of patients with cir-
rhosis suffer ADRs.10 It is estimated that nearly 80% of
these ADRs could be prevented.10 There are studies
available describing the pharmacokinetic alterations for
a wide range of drugs in patients with cirrhosis.8 10–14 All
these studies are of great value and can be very useful
for healthcare professionals. However, they can be difﬁ-
cult to obtain and interpret for a busy healthcare profes-
sional not frequently dealing with patients with cirrhosis.
What is missing is the translation of all literature into a
regularly updated and easy manageable source of infor-
mation on safe prescribing in patients with liver
cirrhosis.15
This study wants to address this problem by developing
advices for the safe use of medications in patients with
liver cirrhosis. To guarantee the quality of these advices,
it is important that the method for evaluating is per-
formed in a uniform, transparent manner leading to a
standardised report.16 Furthermore, advices need to be
manageable by all healthcare professionals dealing with
patients with liver cirrhosis.16 We intend to develop con-
crete and up-to-date advices to prevent alert fatigue and
dissatisfaction by healthcare professionals. The aim of
this study is to describe the systematic method used for
evaluating the safety and optimal dosage of drugs in
patients with liver cirrhosis.
METHODS
Six steps will be performed for evaluating a drug (ﬁgure 1).
Below, the six steps are described in detail. Steps 1–3 will be
performed by a pharmacist with experience in the evalu-
ation of drug safety in the context of clinical decision
support systems (RW). The critical steps are checked by a
second pharmacist/epidemiologist (SB).
Step 1: collection of evidence
Summary of Product Characteristics (SmPC)
Information concerning the pharmacokinetics of the
drug in healthy volunteers and patients with liver cirrho-
sis will be collected from the ofﬁcial Product
Characteristics as published by the responsible author-
ities European Medicines Agency (EMA), Food and
Drug Administration and the Medicines Evaluation
Board in the Netherlands. For products registered by
the EMA, the European Public Assessment Report will
be searched on information about dosage in liver cirrho-
sis. Special warnings regarding the safety of the drug in
patients with liver cirrhosis will also be collected.
Literature search in electronic databases
The search in electronic literature databases aims to
review published literature about the alterations in phar-
macokinetic parameters and the safety of the drug in
patients with liver cirrhosis.
Criteria for inclusion in the literature review are: (1)
the study investigates patients with liver cirrhosis, (2) the
study concerns the drug of interest and (3) the outcome
of the study is safety (ie, adverse events) and/or
(altered) pharmacokinetics. Studies with and without a
control group will be included. If a drug is compared to
another intervention, data about the control group will
be included in the data extraction. There will be no
limit to the time periods searched.
Exclusion criteria are: (1) animal studies, (2) cellular
and molecular research, (3) studies in patients with other
hepatic diseases, such as hepatocellular carcinoma, non-
alcoholic fatty liver disease or primary biliary cholangitis,
that do not mention the inclusion of a subpopulation
with liver cirrhosis and (4) studies about drug-induced
liver injury in patients without liver cirrhosis.
PubMed+EMBASE
These databases will be searched (this includes reviews
published by the Cochrane library) by the search strat-
egy outlined in table 1. A more speciﬁc search will be
performed if there is excessive literature. In this case, a
stepwise search strategy will be used starting with
PubMed as a database. Filters that indicate studies with a
high level of evidence will be used to limit the number
of studies. The pharmacists responsible for the collec-
tion of evidence will judge whether sufﬁcient data are
collected to answer the research question. This step is
checked by another pharmacist and will be discussed
and ﬁnally conﬁrmed by the expert panel.
Citation tracking
Additional articles will be obtained through citation
snowballing to locate primary sources.
Step 2: data extraction and presentation
The following characteristics of included studies will be
extracted: study design, number and characteristics of
included patients and controls (eg, severity of liver cir-
rhosis) and details on the intervention. Concerning the
outcome(s), the following data will be extracted:
▸ (altered) Pharmacokinetics: data on pharmacokinetic
parameters (eg, area under the curve (AUC), elimin-
ation half-life and steady state concentration) of the
drug in patients with liver cirrhosis, preferably com-
pared with patients without liver cirrhosis.
▸ Safety: data on the number of adverse events
observed during use of the drug in patients with cir-
rhosis and on the consequences of these adverse
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events (eg, discontinuation of treatment, dose reduc-
tions), preferably compared with patients without
liver cirrhosis.
Data will be reported in summary tables for each
outcome and sorted by level of evidence. The level of
evidence of each study will be assessed according to the
criteria for treatment harms of the Oxford Centre for
Evidence-Based Medicine.17 In a separate table, narrative
reviews will be included as level ﬁve evidence to reﬂect
on published expert opinions. The summary tables will
be checked by a second pharmacist.
All data will be summarised in an assessment report.
This standardised report will contain:
▸ Data from the SmPC
▸ Details on the electronic database search (search
strategy, study selection process in a ﬂow chart)
▸ Summary tables with pharmacokinetic and safety data
▸ References
Step 3: classification and suggested dose
All information from the report will be used to suggest a
safety classiﬁcation and a dose per individual drug, if
applicable sorted by severity of liver cirrhosis. The sever-
ity will be expressed using the Child-Pugh classiﬁcation.4
Safety classification
To support healthcare providers and patients to efﬁ-
ciently judge drug safety in liver cirrhosis, we designed a
safety classiﬁcation (table 2). For drugs in liver cirrhosis,
we will use the following categories: safe, no additional
risks known, additional risks known, unsafe and
unknown. Drugs that have not been evaluated are
placed in the category ‘not yet classiﬁed’.
Suggested dose
Pharmacokinetic data will be used to judge whether a
dose adjustment is necessary in patients with cirrhosis. It
applies for most drugs that if the AUC is more than
doubled, a dose reduction will be recommended.5
Exceptions are, for instance, drugs that do not have a
concentration–effect relationship or drugs with a narrow
therapeutic range. Both the proposed classiﬁcation and
Figure 1 Flow chart of the
six-step process used per drug
for evaluating the safety and
optimal dosage in liver cirrhosis.
Table 1 Proposed search strategy for PubMed and
EMBASE
Database Search query
PubMed (“Liver cirrhosis”[Mesh] OR cirrho*[ti] OR
“hepatic impairment”[ti] OR “liver
impairment”[ti] OR “hepatic dysfunction”[ti] OR
“liver dysfunction”[ti] OR “hepatic
insufficiency”[ti] OR “liver insufficiency”[ti])
AND (“X”[Mesh] OR “X”[tiab]) AND
“humans”[MeSH Terms]
EMBASE ‘liver cirrhosis’/exp OR cirrho*:ti OR ‘hepatic
impairment’:ti OR ‘liver impairment’:ti OR
‘hepatic dysfunction’:ti OR ‘liver dysfunction’:ti
OR ‘hepatic insufficiency’:ti OR ‘liver
insufficiency’:ti AND (‘X’/exp OR ‘X’:ab,ti) AND
[humans]/lim
X, name of drug to be evaluated.
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suggested dose are checked by a second pharmacist,
before discussion by the expert panel.
Step 4: discussion and conclusion by the expert panel
An expert panel will evaluate the validity and clinical
relevance of the initial classiﬁcation, the suggested dose
and the data extraction. This panel will meet ﬁve times
during the study to discuss the assessment reports.
Comments and opinions of the panel will be added to
the initial report, such as recommendations for thera-
peutic drug monitoring or extra monitoring of liver
function tests and/or clinical response. The ﬁnal report
is a combination of the available evidence and expert
opinions. The expert panel will conclude by consensus.
If there are different interpretations within the expert
panel, these will be included as ‘expert comments’ in
the assessment report.
The expert panel consists of the following specialists:
the pharmacist responsible for the data collection,
extraction and initial evaluation (RW), professionals
with expertise regarding our two main outcomes;
altered safety or pharmacokinetics in patients with liver
cirrhosis (DB and NH), representatives of the specialists
responsible for prescribing: hepatologists ( JD and HM),
general practitioner (MB), representatives of specialists
responsible for dispensing: clinical pharmacists (DB and
NH), a community pharmacist (SvP), a clinical
pharmacokinetics assessor of the Medicines Evaluation
Board (MM-S) and two pharmacists working with the
national drug databases in the Netherlands
(Pharmabase and G–Standard: MK and SB). Each
expert has speciﬁc expertise in the treatment of patients
with liver cirrhosis, in clinical pharmacology and/or the
implementation of the outcomes. The general practi-
tioner and community pharmacist will contribute to the
implementation from the perspective of primary care.
The pharmacists working for the national drug data-
bases will assure that the advices can be implemented in
clinical decision support systems. There is also an epi-
demiologist (SB) in the expert panel who will pay atten-
tion to the methodology.
All conﬂicts of interest of the members of the expert
panel will be identiﬁed, disclosed and published on the
website (see implementation). The chair of the expert
panel (SB) has no conﬂicts of interest.
Step 5: implementation
Advices about the safety of a drug and the optimal
dosage in patients with liver cirrhosis will be implemen-
ted in the two national drug databases in the
Netherlands (Pharmabase and G-Standard). This will
generate speciﬁc alerts for healthcare professionals
when they prescribe or dispense a drug with risks to a
patient with liver cirrhosis.
Table 2 Safety classification of drugs used in liver cirrhosis
Description Action
Safe The drug has been evaluated in patients with liver
cirrhosis, and no increase in harm was found. The safety
of the drug is supported by pharmacokinetic studies and/or
safety studies over a long period.
It might be necessary to use an adjusted dose.
This drug can be used by patients with liver
cirrhosis.
No additional
risks known
Limited data suggest that this drug does not increase
harm in patients with liver cirrhosis in comparison with
persons without cirrhosis. Drugs estimated as ‘minor
influenced by cirrhosis’ based on pharmacokinetics* can
also be classified in this category if the expert panel
agrees.
It might be necessary to use an adjusted dose.
The drug can be used in patients with liver
cirrhosis.
Adverse drug reactions need to be monitored.
Additional risks
known
Limited data suggest an increase in patient harm in
patients with cirrhosis compared with persons without
cirrhosis. However, the number of studies is limited and/or
the studies show contradictory results about the safety in
patients with liver cirrhosis.
This drug should preferably not be used in
patients with liver cirrhosis if there is a safer
alternative available.
Adverse drug reactions need to be monitored.
Unsafe Data indicate that this drug is not safe in patients with liver
cirrhosis.
This drug should be avoided in patients with
liver cirrhosis.
Unknown For this drug, insufficient data are available to evaluate the
safety in patients with liver cirrhosis.
This drug should preferably not be used in
patients with liver cirrhosis if there is a safer
alternative available.
Individual judgement of therapeutic need vs
additional risks in patients with liver cirrhosis.
Adverse drug reactions need to be monitored.
Not yet
classified
The drug has not been evaluated for safety in patients
with liver cirrhosis.
No advice for action can be given
*Drugs are classified as ‘minor influenced by cirrhosis’ if they are cleared <20% by the liver.5
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The advices will also be published on a website. On this
website, a summary will be included which starts with the
key recommendations (ie, safety classiﬁcation of drug and
dosing advices) and describes background information
on the advice and body of evidence (ie, number of
studies retrieved, number of participants and level of evi-
dence of the studies). The full assessment report can be
accessed through a hyperlink. The advices will be in
Dutch, since they will be implemented in national clinical
decision support systems. The summary of ﬁnding tables
derived from the (English) literature will be left in
English. Conﬂicts of interest of the members of the
expert panel will be mentioned on the website.
There will also be a part on the website intended for
patients with liver cirrhosis. This part will contain a
simple, patient-friendly version of the advices with direc-
tions to consult their doctor or pharmacist in case of
further questions. These advices will be made in collabor-
ation with the Dutch Liver Patients Association. Before
publication of the website, the ﬁnding and understanding
of the content will be tested by patients and healthcare
professionals. Via user testing, a group of patients and a
group of healthcare professionals will test the website.18 If
issues emerge from this testing, they will be solved and
the process will be repeated until no more issues emerge.
Step 6: continuity
To assure up-to-date advices, literature searches will be
saved and checked yearly for relevant literature.
Comments from patients and professionals using the
guidelines will be reviewed and included, if applicable.
The expert panel will check yearly if the advices need to
be updated based on their speciﬁc (clinical) expertise.
Drugs to be evaluated
A selection of drugs will be evaluated: (A) drugs used to
treat (complications of) liver cirrhosis, such as urso-
deoxycholic acid and β–blockers and (B) drugs that are
prescribed frequently to the general population, such as
antibiotics and analgesics. An overview of the drugs that
will be evaluated in this study is presented in table 3.
DISCUSSION
We have developed a systematic method to evaluate the
safety and optimal dosage of drugs in patients with liver
cirrhosis. Our method combines a systematic literature
review with expert opinion and contains many aspects of
the development of guidelines. We used the AGREE
Reporting Checklist to ensure that important issues are
included in the study protocol.25 Our approach will
produce a standardised assessment report per drug. It is
important that this report contains the information
healthcare professionals need for clinical decision-
making. In the development of an assessment report, we
were inspired by a checklist that identiﬁes the most
important elements that should be included in drug–
drug interaction management guidelines.16 One of the
main domains of the checklist was the ‘management
strategy’. We designed a safety classiﬁcation to help
healthcare professionals to efﬁciently judge the safety
of a drug in a patient with cirrhosis. Safety classiﬁca-
tions are used in other conditions where careful con-
sideration is needed to judge the safety of a drug,
such as Long QT-Syndrome,26 porphyria27 and preg-
nancy/lactation.28 All classiﬁcations have in common
that the number of categories is limited, that a
description is available why drugs are classiﬁed in a
certain category and that a category can be related to
an advice towards a healthcare provider. We think our
safety classiﬁcation results in concrete advices, thereby
preventing dissatisfaction and alert fatigue of health-
care professionals.
The strengths of our study are the combination of evi-
dence from the literature and expert opinion, the imple-
mentation in clinical decision support systems and the
continuity. First, the published evidence of drugs in liver
Table 3 Drugs to be evaluated in the current study
Box A: drugs to treat
(complications of) liver
cirrhosis19-24
Box B: most frequently
used drugs in the general
population*
Metabolic syndrome Analgesics
Insulins Paracetamol
Oral antidiabetics
Dyslipidemia
NSAIDs
Opioids
Antilipemics Antibiotics
(anti) Hepatitis B/C Tetracyclines
Nucleos(t)ide analogues
Interferon
Direct-acting antivirals
Sulfonamides
and trimethoprim
Macrolides
Other antibioticsPBC/AIH
Gastro-intestinal drugs
Antacids
Corticosteroids
H2-receptor antagonists
Ursodeoxycholic acid
Propulsives
Azathioprine
Stimulant laxatives
Mycophenolate mofetil
Bulk-forming laxatives
Infections
Cardiovascular drugs
Chinolons
Antithrombotics
Penicillins
Calcium antagonists
Esophageal varices
RAS-inhibitors
Proton pump inhibitors
Portal hypertension
Beta blocking agents
Hepatorenal syndrome
Terlipressin
Ascites
Diuretics
Albumin
Hepatic encephalopathy
Lactitol
Lactulose
Rifaximin
*Based on number of users of prescribed drugs in the
Netherlands according to the GIP-database 2013 (www.
gipdatabank.nl).
PBC, primary biliary cholangitis; AIH, autoimmune hepatitis
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cirrhosis is variable, and studies often have a limited
scope or a selective patient population. Combination
with expert opinion adds the clinical and pharmaco-
logical experience to the published literature. This com-
bination will make it possible to give speciﬁc advices,
which is even more relevant in case little published lit-
erature is available. Second, the advices will be imple-
mented in the two main clinical decision support
systems in the Netherlands, automatically reaching all
hospitals, community pharmacies and general practices.
Healthcare professionals will receive a notiﬁcation if a
contraindicated drug is prescribed or dispensed to a
patient with liver cirrhosis. This implementation can
quickly result in a huge improvement in the medication
safety of patients with cirrhosis in the Netherlands. We
believe that this Dutch approach of monitoring the
safety of drug use is unique,29 and hope to inspire
others to implement this in their healthcare systems.
Third, to safeguard continuity, it is important that this
guideline will be updated regularly and that these
updates will be included in new signals. The advices will
get updated yearly if there is new literature or if we
receive comments. This is a major advantage in compari-
son to all reviews published on this topic.
We expect that we will not perform a standard system-
atic review for all drugs.30 Albumin, for example, has
been safely used for a long period of time in patients
with liver cirrhosis and many studies have been pub-
lished, also in patients with liver cirrhosis. In this case,
we will include literature from the highest level of evi-
dence and stop extracting if we have sufﬁcient informa-
tion to classify the drug. The expert panel will also
decide whether sufﬁcient information is collected to
classify the drug. Another limitation is that we will evalu-
ate a restricted number of drugs in this study. Future
research can enlarge the amount of drugs evaluated.
Also, this study will expose knowledge gaps in the
current literature with respect to the pharmacokinetics
and safety of certain drugs in liver cirrhosis. Speciﬁc
pharmacokinetic or pharmacodynamic studies can pos-
sibly ﬁll this gap. Another interesting future research
area is the implementation; do healthcare professionals
follow our advices? How can the information obtained
in our study be used to improve ofﬁcial drug labelling?
Ultimately, does our study result in optimisation of medi-
cation use, that is, reduction in the number of adverse
drug events experienced by patients with liver cirrhosis?
In conclusion, this protocol describes a method to
evaluate the safety and optimal dosage of drugs in
patients with liver cirrhosis. This will lead to advices con-
cerning the safety and optimal dosage of the drugs
mostly used in liver cirrhosis and reveal gaps in the lit-
erature for future research.
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